Cyclocreatine
Based on 1 publication(s) in Google Scholar
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.78%
- CAS No.: 35404-50-3
- Formule: C5H9N3O2
- Masse moléculaire:143.15
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cyclocreatine
More
Activité biologique
Description
In Vitro
Cyclocreatine (5 or 10 mM, 24 or 40 h) improves extracellular acidification rate (ECAR) which is accompanied by less Autophagy, increases mTOR signaling and cell viability in bone marrow-derived macrophages[2].
Cyclocreatine (0-50 mM, 24 h) suppresses creatine metabolism, proliferation and creatine uptake in prostate cancer cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Bone marrow-derived macrophages
-
Concentration:5 or 10 mM
-
Incubation Time:incubation for 24 or 40 h
-
Result:Increased mTOR signaling and cell viability in bone marrow-derived macrophages.
-
Cell Line:Murine and human prostate cancer cells
-
Concentration:0-50 mmol/L
-
Incubation Time:24 h
-
Result:Impaired in vitro proliferation of both human and murine prostate cancer cells
In Vivo
Cyclocreatine (0.28 mg/g, drink, supplementation daily from 10-week to 8 months) rescues microgliosis and clustering and moderates neurite dystrophy in TREM2−/− 5XFAD mice[2].
Cyclocreatine (40 mg, gavage, daily for 1 month) significantly reduces liver metastatic burden and affects prostate cancer progression in a model of liver metastasis of mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:AMI-intact dog model[1]
-
Dosage:500 mg/kg
-
Administration:i.v., a single dose for 60 min
-
Result:Preserved 85% of pre-ischemic ATP level (loss of only 15%) and 97% of the CrP (loss of 3%) during ischemia, as well as immediately restored over 80% of contractile function during the 2 h of reperfusion in AMI-intact dog model.
-
Animal Model:5XFAD and TREM2−/− 5XFAD mice
-
Dosage:0.28 mg/g
-
Administration:Drinking water supplementation with cyclocreatine daily from 10-week to 8 months
-
Result:Improved microglial metabolism and the protective response to Aβ plaques in TREM2-deficient 5XFAD mice.
Chemical Information
-
CAS No. 35404-50-3
-
Appearance Solid
-
Masse moléculaire 143.15
-
Formule C5H9N3O2
-
Color White to yellow
-
SMILES
O=C(O)CN1CCNC1=N
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Oncoimmunology
CARD9 deficiency promotes pancreatic cancer growth by blocking dendritic cell maturation via SLC6A8-mediated creatine transport. [Abstract]2023 Apr 19;12(1):2204015. PMID: 37089447
Solvant et solubilité
In Vitro:
1M HCl : 100 mg/mL (698.57 mM; ultrasonic and adjust pH to 2 with HCl)
H2O : 5 mg/mL (34.93 mM; ultrasonic and warming and heat to 60°C)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 10 mg/mL (69.86 mM); Clear solution; Need ultrasonic and warming
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Salwa A Elgebaly, et al. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion. Expert Rev Cardiovasc Ther. 2019 Sep;17(9):683-697. [Content Brief]
[2]. Tyler K Ulland, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. 2017 Aug 10;170(4):649-663.e13. [Content Brief]
[3]. Patel R, et al. Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression[J]. Cancer Res. 2022 Jul 18;82(14):2565-2575. [Content Brief]
[5]. Cacciante F, et al. Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency[J]. Sci Rep. 2020 Oct 27;10(1):18361 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / 1M HCl | 1 mM | 6.9857 mL | 34.9284 mL | 69.8568 mL | 174.6420 mL |
| 5 mM | 1.3971 mL | 6.9857 mL | 13.9714 mL | 34.9284 mL | |
| 10 mM | 0.6986 mL | 3.4928 mL | 6.9857 mL | 17.4642 mL | |
| 15 mM | 0.4657 mL | 2.3286 mL | 4.6571 mL | 11.6428 mL | |
| 20 mM | 0.3493 mL | 1.7464 mL | 3.4928 mL | 8.7321 mL | |
| 25 mM | 0.2794 mL | 1.3971 mL | 2.7943 mL | 6.9857 mL | |
| 30 mM | 0.2329 mL | 1.1643 mL | 2.3286 mL | 5.8214 mL | |
| 1M HCl | 40 mM | 0.1746 mL | 0.8732 mL | 1.7464 mL | 4.3660 mL |
| 50 mM | 0.1397 mL | 0.6986 mL | 1.3971 mL | 3.4928 mL | |
| 60 mM | 0.1164 mL | 0.5821 mL | 1.1643 mL | 2.9107 mL | |
| 80 mM | 0.0873 mL | 0.4366 mL | 0.8732 mL | 2.1830 mL | |
| 100 mM | 0.0699 mL | 0.3493 mL | 0.6986 mL | 1.7464 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cyclocreatine Related Classifications
HY-W017540 Related Classifications
Powered by Bioz